A new SARS-CoV-2 spike enhances replication. During the evolution of SARS-CoV-2 in humans a D614G substitution in the spike (S) protein emerged and became the predominant circulating variant (S-614G) of the COVID-19 pandemic. However, whether the increasing prevalence of the variant represents an advantage that improves replication and/or transmission in humans or merely due to founder effects remains elusive.
Isogenic SARS-CoV-2 variants were generated and showed that the S-614G variant has enhanced binding to human host cell surface receptor angiotensin-converting enzyme 2 (ACE2), ) increased replication in primary human bronchial and nasal airway epithelial cultures as well as in a novel human ACE2 knock-in mouse model, and markedly increased replication and transmissibility in hamster and ferret models of SARS-CoV-2 infection.
Collectively, data shows that while the S-614G substitution results in subtle increases in binding and replication in vitro, it provides a real competitive advantage in vivo, particularly during the transmission bottle neck, providing an explanation for the global predominance of S-614G variant among the SARS-CoV-2 viruses currently circulating.
In late 2019, severe acute respiratory syndrome coronavirus 2(SARS-CoV-2) emerged in Wuhan, Hubei province, China, and rapidly developed into the COVID-19 pandemic. By December 2020, 70 million cases and 1.5 million deaths have been confirmed. In vulnerable groups of people, SARS-CoV-2 causes a life-threatening pneumonia. Cell entry of SARS-CoV-2 is dependent on the interaction of the spike glycoprotein and ACE23, a homotrimeric class I fusion protein consists of two subunits S1 and S2, separated by a protease cleavage site.
S1 forms a globular head and is essential for receptor binding, while S2 mediates fusion of the viral envelope with host cell membranes. During entry, the receptor-binding domain (RBD) within the S1 subunit binds ACE2, generating conformational changes in the S2 subunit, facilitating virus internalization. S-D614G, a protein variant containing a substitution in the S protein outside of the RBD, is thought to cause a conformational change, improving ACE2 binding and increasing the
probability of infection.
As the pandemic progressed, the SARS-CoV-2 S-614G variant rapidly superseded the parental S-614D variant in frequency to become globally dominant. Such a shift in genotype frequency might be caused by a founder effect following introduction into a highly interconnected population. However, the S-614G variant may confer a fitness advantage compared to S-614D.
However, some studies suggest the S-614G substitution may confer a fitness advantage by improving entry. To address the role that the S-D614G substitution has played in the dissemination and predominance of this SARS-CoV-2 variant during the COVID-19 pandemic, we characterized S protein binding to human ACE2 (hACE2) and replication kinetics in vitro and evaluated infection and transmission dynamics in vivo using three different animal models. The data show that the S-D614G substitution confers increased binding to the hACE2 receptor and increased replication in primary human airway epithelial cultures.
Moreover, comparison of recombinant isogenic SARS-CoV-2 variants demonstrates that S-614G substitution provides competitive advantage in a hACE2 knock-in mouse model, and markedly increases replication and transmission in Syrian hamster and ferret models. To address the role that the S-D614G substitution has played in the dissemination and predominance of this SARS-CoV-2 variant during the COVID19 pandemic, we characterized S protein binding to human ACE2 (hACE2) and replication kinetics in vitro and evaluated infection and transmission dynamics in vivo using three different animal models.
Brought to you by Febo Health
Add a Comment